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Viruses can exploit a variety of strategies to evade immune surveillance by cytotoxic T lymphocytes (CTL),
including the acquisition of mutations in or adjacent to CTL epitopes. Recently, an amino acid substitution
(R384G) in an HLA-B*2705-restricted CTL epitope in the influenza A virus nucleoprotein (nucleoprotein
containing residues 383 to 391 [NP383–391]; SRYWAIRTR, where R is the residue that was mutated) was as-
sociated with escape from CTL-mediated immunity. The effect of this mutation on the in vitro influenza A
virus-specific CTL response was studied. To this end, two influenza A viruses, one with and one without the
NP383–391 epitope, were constructed by reverse genetics and designated influenza viruses A/NL/94-384R and
A/NL/94-384G, respectively. The absence of the HLA-B*2705-restricted CTL epitope in influenza virus A/NL/
94-384G was confirmed by using 51Cr release assays with a T-cell clone specific for the NP383–391 epitope. In
addition, peripheral blood mononuclear cells (PBMC) stimulated with influenza virus A/NL/94-384G failed to
recognize HLA-B*2705-positive target cells pulsed with the original NP383–391 peptide. The proportion of
virus-specific CD8 gamma interferon (IFN-)-positive T cells in in vitro-stimulated PBMC was determined
by intracellular IFN- staining after restimulation with virus-infected autologous B-lymphoblastoid cell lines
and C1R cell lines expressing only HLA-B*2705. The proportion of virus-specific CD8 T cells was lower in
PBMC stimulated in vitro with influenza virus A/NL/94-384G obtained from several HLA-B*2705-positive
donors than in PBMC stimulated with influenza virus A/NL/94-384R. This finding indicated that amino acid
variations in CTL epitopes can affect the virus-specific CTL response and that the NP383–391 epitope is the most
important HLA-B*2705-restricted epitope in the nucleoprotein of influenza A viruses.
Cytotoxic T lymphocytes (CTL) play an important role in the
control of viral infections, including those caused by influenza
viruses. It has been shown that in mice, CTL contribute to
protective immunity against influenza viruses of various sub-
types (25). In addition, influenza A virus-specific CTL in hu-
mans were found to reduce virus titers in the lungs and mor-
bidity upon infection (27). To evade host CTL responses,
viruses have developed a variety of mechanisms to prevent
recognition by specific CTL (24, 30). These mechanisms in-
volve major histocompatibility complex (MHC) class I down-
regulation, as described for the human immunodeficiency virus
type 1 Nef protein (11, 40) and the adenovirus E3/19K protein
(8), and blocking of antigen presentation of viral epitopes, as
described for certain herpesvirus proteins (22, 23). Alterna-
tively, viruses can accumulate in or adjacent to CTL epitopes
mutations that affect peptide processing and presentation,
binding to MHC class I molecules, and/or recognition by spe-
cific T cells (20, 45). This escape mechanism has been de-
scribed predominantly for chronic virus infections, such as
those caused by lymphocytic choriomeningitis virus (29, 32),
Epstein-Barr virus (1, 9, 13, 14, 17), human immunodeficiency
virus (7, 12, 18, 19, 24, 28, 31, 33, 34), hepatitis B virus (2, 3),
and hepatitis C virus (10, 44).
Recently, amino acid sequence variations in CTL epitopes
in the nucleoprotein (NP) of influenza A viruses were iden-
tified (5, 41). In the HLA-B*3501-restricted epitope
NP418–426 (NP containing residues 418 to 426), variations were
observed in the T-cell receptor contact residues (5). These
variants emerged in a chronological order, and CTL specific
for older variants failed to recognize the mutated versions of
the same epitope. In addition, an amino acid sequence varia-
tion was observed at position 384 of the NP. An arginine at this
position is an anchor residue for the HLA-B*0801-restricted
epitope NP380–388 (ELRSRYWAI) and the HLA-B
*2705-re-
stricted epitope NP383–391 (SRYWAIRTR) (21). The observed
R384G mutation resulted in the loss of the anchor residue and,
as a result, abolished recognition by CTL (37, 41). Although
the rapid fixation of the mutation was explained by small se-
lective advantages and population dynamics in a theoretical
model (16), it is unclear to what extent a single amino acid
substitution in a CTL epitope affects the overall virus-specific
CTL response in humans.
In this study, this issue was addressed in vitro by using
peripheral blood mononuclear cells (PBMC) from HLA-
B*2705-positive individuals and genetically engineered recom-
binant influenza viruses containing an arginine or a glycine at
position 384 (but otherwise identical) and therefore possessing
or not possessing the HLA-B*2705-restricted epitope NP383–391
(SRYWAIRTR). Using these viruses for the stimulation of
PBMC, we assessed the in vitro CTL response. It was found
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that the R384G substitution significantly impaired the influ-
enza virus-specific CTL response in vitro.
MATERIALS AND METHODS
Plasmids and site-directed mutagenesis. For the generation of recombinant
influenza viruses, RNA was extracted from culture supernatants containing in-
fluenza virus A/Netherlands/18/94 (A/NL/18/94) by using a High Pure RNA
isolation kit (Roche Diagnostics GmbH, Mannheim, Germany). The RNA was
used in a single-tube reverse transcription-PCR to amplify viral NP segments.
After annealing of the primers AGCAAAAGCAGGGT and AGTAGAAACA
AGGGTATTTTTC, first-strand synthesis was carried out with 50-l volumes of
20 mM Tris-HCl buffer (pH 8.8) containing 10 mM KCl, 10 mM (NH4)2SO4, 2
mM MgSO4, 0.1% Triton X-100, 0.1 mg of bovine serum albumin (BSA)/ml, 10
mM deoxynucleoside triphosphates, 10 mM dithiothreitol, RNasin, 5 IU of
Superscript II reverse transcriptase, and 5 IU of Pfu Turbo DNA polymerase
(Stratagene, La Jolla, Calif.). After incubation for 45 min at 42°C, the mixture
was heated at 95°C for 3 min, followed by 40 cycles of denaturation (1 min at
95°C), annealing (2 min at 37°C), and elongation (3 min at 72°C). For the
addition of BsaI restriction sites, an additional amplification of 30 cycles was
performed with the primers CTAGGTCTCTTATTAGTAGAAACAAGG and
GGGAGGTCTCCGGCCAGCAAAAGCAGG (underlining indicates restric-
tion sites). The amplicon was purified by electrophoresis on agarose gels accord-
ing to standard methods and inserted between the human polymerase I promoter
and the hepatitis delta ribozyme sequence of plasmid pSP72-PhuThep (15).
For site-directed mutagenesis, the coding sequence of the NP gene of influ-
enza virus A/NL/18/94 was amplified by PCR with the primers CAGCGGCCG
CATGGCGTCCCAAGGC and CACTCGAGTTAATTGTCGTACTCCT
CTGC and cloned into pBluescript (Stratagene) after digestion with NotI and
XhoI. Using this plasmid as a template, site-directed mutagenesis was performed
by PCR in order to obtain an arginine at position 384 instead of a glycine
(G384R) as previously described (39). The mutated sequence was exchanged by
using restriction site SphI in the NP gene and restriction site XhoI in pBluescript,
3 of the insert. Subsequently, the SacI fragment with the mutation at position
384 was exchanged for SacI fragments in genomic constructs of the NP gene of
influenza A virus A/NL/18/94. The nucleotide sequences of all cloned NP genes
were determined by using standard procedures as previously described (41) in
order to confirm the identity of the sequences.
Plasmid pHMG-NP, from which the NP of influenza virus A/PR/8/34 was
transcribed, was kindly provided by P. Palese. The bidirectional reverse genetics
plasmids pHW181 through pHW188 for the transcription of viral gene segments
of influenza virus A/WSN/33 were kindly provided by R. G. Webster.
Generation of viruses. The unidirectional plasmid of the genomic construct of
the NP of A/NL/18/94 was transfected into 293T cells with the bidirectional con-
structs containing the PB1, PB2, PA, HA, NA, M, and NS gene segments of
A/WSN/33 and pHMG-NP expressing the NP of PR/8/34. For this purpose, 106
293T cells were cultured overnight in Dulbecco minimal essential medium (Cam-
brex, East Rutherford, N.J.) supplemented with 10% fetal calf serum (FCS), 2 mM
L-glutamine, and 100 IU of penicillin/ml and 100 g of streptomycin/ml (antibiotics)
in gelatin-coated 10-cm petri dishes. The cells then were transfected with 5 g of
each of the plasmids by the calcium phosphate precipitation method as described
previously (15). After 24 h, the cells were washed with phosphate-buffered saline
(PBS), and 10 ml of Dulbecco minimal essential medium containing 2% FCS was
added. After another 24 h, the culture supernatants of the transfected 293T cells
were harvested, and infectious virus titers were determined as previously described
(36). Titers of 103 50% tissue culture infective doses/ml were obtained routinely with
the A/NL/94-384G and A/NL/94-384R constructs. Subsequently, virus stocks were
prepared by infecting confluent Madin-Darby canine kidney (MDCK) cells in 162-
cm2 flasks with 1 ml of supernatant from the transfected 293T cells in 4 ml of Eagle
minimal essential medium (Cambrex) supplemented with 4% BSA, 0.02 M HEPES,
0.01 M NaHCO3, antibiotics, and 0.1% trypsin (infection medium) at 37°C for 1 h.
The cells were washed once with PBS and then cultured at 37°C in infection medium.
After 3 days, culture supernatants were harvested, cleared by low-speed centrifuga-
tion, divided into aliquots, and stored at70°C until use. Viruses with the NP383–391
epitope and viruses without the NP383–391 epitope were designated A/NL/94-384R
and A/NL/94-384G, respectively. Upon infection of MDCK cells, virus titers were
amplified up to 107 50% tissue culture infective doses/ml for both viruses.
PBMC. PBMC from healthy HLA-B*2705-positive blood donors were isolated
from heparinized blood (Sanquin Bloodbank, Rotterdam, The Netherlands) by
density gradient centrifugation with lymphocyte separation medium (ICN Bio-
medicals/Cappel, Aurora, Ohio) and cryopreserved at 135°C. Genetic subtyp-
ing was performed in the Laboratory for Histocompatibility and Immunogenetics
at the Sanquin Bloodbank by using a commercial typing system (GenoVision,
Vienna, Austria).
In vitro stimulation of PBMC with influenza A viruses. PBMC were resus-
pended in RPMI 1640 medium containing 25 mM HEPES buffer and L-glu-
tamine (Cambrex) and supplemented with 10% FCS and antibiotics (R10F). Five
million PBMC were infected with influenza virus A/NL/94-384G, A/NL/94-384R,
or Resvir-9, a reassortant of strains A/Puerto Rico/8/34 (H1N1) and A/Nan-
chang/933/95 (H3N2) containing the NP, HA, and NA of A/Nanchang/933/95. A
multiplicity of infection of 3 in a volume of 5 ml of R10F was used as described
previously (4). After 1 h at 37°C, the cells were resuspended in RPMI 1640
medium supplemented with 10% human AB serum (Sanquin Bloodbank), anti-
biotics, and 20 M -mercaptoethanol and added to noninfected PBMC at a
ratio of 1:1 in a 25-cm2 culture flask. After 48 h of stimulation, recombinant
interleukin 2 was added to a final concentration of 50 IU/ml. After an additional
7 to 8 days, the cells were used as effector cells in 51Cr release assays and for the
enumeration of virus-specific CD8 T cells by intracellular gamma interferon
(IFN-) staining (see below).
CD8-T-cell clones. The generation of a CD8-T-cell clone directed against
the HLA-B*2705-restricted epitope NP383–391 derived from the NP was de-
scribed previously (41). A CD8-T-cell clone directed against the immunodom-
inant and conserved HLA-A*0201-restricted epitope M158–66 derived from the
matrix protein (M1) was established by similar procedures.
Isolation of CD8 T cells. CD8 T cells were isolated from effector cell
populations by magnetic sorting with a CD8 cell selection kit (Dynal Biotech
GmbH, Hamburg, Germany). The cells were washed once with PBS supple-
mented with 2% FCS (P2F) and subsequently resuspended in P2F at a concen-
tration of 107/ml. Capture Dynabeads were added to the cell suspension at a
Dynabead/CD8-T-cell ratio of 8:1. After 30 min of incubation on ice, the
mixture of Dynabeads and cells was washed five times with 5.0 ml of P2F. The
Dynabeads, together with the attached cells, were reconstituted in 200 l of
RPMI 1640 medium supplemented with 1% FCS. To detach the cells from the
Dynabeads, 20 l of DETACHaBEAD (Dynal Biotech) was added. After 1 h of
incubation at 20°C, the released cells were isolated, washed once with R10F, and
used as effector cells in 51Cr release assays with C1R cells as target cells.
Target cells. Autologous B-lymphoblastoid cell lines (BLCL), produced as
described previously (38), and two C1R cell lines, kindly provided by P. Romero
(C1R cell line) and J. Lopez de Castro (HLA-B*2705-transfected C1R cell line
[C1R-B27]), were used as target cells. Peptide labeling was performed by incu-
bating 106 cells overnight with 5 M peptide in 1 ml of R10F. Peptides were
manufactured, purified by high-pressure liquid chromatography, and analyzed by
mass spectrometry (Eurogentec, Seraing, Belgium). For exogenous protein la-
beling, 50 g of recombinant influenza virus NP (rNP), derived from influenza
virus A/HK/2/68 (rNP-HK) or A/NL/18/94 (rNP-NL), was added to 106 cells in
1 ml of R10F as described previously (42). For infection with influenza virus
A/NL/94-384G and A/NL/94-384R, target cells were infected at a multiplicity of
infection of 3 in a volume of 1 ml. After incubation for 1 h at 37°C, the cells were
resuspended in R10F and incubated for 16 to 18 h. BLCL and C1R cells were
equally susceptible to infection with influenza virus A/NL/94-384G and A/NL/
94-384R, as determined by immunofluorescence assays with a fluorescein iso-
thiocyanate-conjugated monoclonal antibody (MAb; Dako, Glostrup, Denmark)
directed to the NP.
51Cr release assays. Target cells were resuspended in RPMI 1640 medium
supplemented with 0.1% BSA and antibiotics (R0.1B). Next, 5  105 target cells
were labeled with 50 Ci of Na2[51Cr]O4 in R0.1B for 1 h at 37°C. After
incubation, the cells were washed three times with R10F and adjusted to a
concentration of 105/ml. Subsequently, 50-l samples of target cells were incu-
bated with PBMC stimulated in vitro with influenza virus A/NL/94-384G or
A/NL/94-384R at effector cell/target cell (E/T) ratios of 80, 40, 20, 10, or 5 or with
purified CD8-T-cell populations or T-cell clones at E/T ratios of 10, 5, 2.5, and
1. Target cells were also incubated with 100 l of 10% Triton X-100 or R10F to
determine maximum release and spontaneous release, respectively. After 4 h of
incubation at 37°C, the supernatants were harvested (Skatron Instruments, Ster-
ling, Va.), and radioactivity was measured by gamma counting. The percentage
of specific lysis was calculated with the following formula: (experimental release
 spontaneous release)/(maximum release  spontaneous release)  100%.
51Cr release assays were performed in triplicate or quadruplicate, and the data
are presented as averages.
Intracellular IFN- staining and flow cytometry. PBMC expanded in vitro
after stimulation with influenza virus A/NL/94-384G or A/NL/94-384R were
resuspended and adjusted to a concentration of 106 cells/ml in R10F supple-
mented with Golgistop (monensin; Pharmingen, Alphen a/d Rijn, The Nether-
lands). A total of 100,000 effector cells were incubated with 2  105 stimulator
cells, which had been infected or incubated with rNP or peptides or left un-
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treated, for 6 h at 37°C in U-bottom plates. Subsequently, intracellular IFN-
staining was performed as described previously (6). In brief, the cells were
washed with PBS containing 2% FCS (P2F) and Golgistop, stained with MAbs
directed to CD3 (Becton Dickinson, Alphen a/d Rijn, The Netherlands) and
CD8 (Dako), fixed and permeabilized with Cytofix and Cytoperm (Pharmingen),
and stained with an MAb specific for IFN- (Pharmingen). At least 103 gated
CD3 CD8 events were acquired by using a FACSCalibur (Becton Dickinson)
flow cytometer. The data were analyzed by using the software program Cell
Quest Pro (Becton Dickinson). The data were expressed as the percentage of
virus-specific IFN--positive (IFN-) CD8 T cells in PBMC cultures and as
the percentage of virus-specific IFN- cells in the CD8-T-cell fraction. The
relative reduction in the virus-specific IFN- CD8 response was calculated
according to the following formula: 100  [(percentage of IFN- CD8 T cells
after restimulation with influenza virus A/NL/94-384G  100)/percentage of
IFN- CD8 T cells after restimulation with influenza virus A/NL/94-384R)].
Routine staining with MAbs was carried out with 1  105 to 5  105 cells for 30
min at 4°C. In this way, the proportions of CD3, CD4, and CD8 cells could
be determined.
Statistical analysis. It was assumed that the data obtained were not normally
distributed because of the use of different blood donors. Therefore, statistical anal-
ysis was performed on the difference between A/NL/94-384G- and A/NL/94-384R-
stimulated PBMC in the responses to influenza virus A/NL/94-384G- and A/NL/94-
384R-infected target cells by using a one-way analysis of variance (ANOVA).
RESULTS
Validation of infection with influenza viruses A/NL/94-384G
and A/NL/94-384R in vitro. To verify that target cells were
equally susceptible to infection with influenza virus A/NL/94-
384G and A/NL/94-384R, immunofluorescence assays were per-
formed with BLCL infected with either virus. It was found that
the numbers of infected cells were similar, as determined by
positive staining for NP (data not shown). In addition, the expres-
sion of MHC class I-bound epitopes on the surface of BLCL
infected with influenza A viruses A/NL/94-384G and A/NL/94-
384R and the subsequent recognition by CTL were compared to
confirm that they were on the same order of magnitude (Fig. 1).
To this end, 51Cr release assays were performed with HLA-
A*0201- and HLA-B*2705-positive BLCL as target cells and
CD8-T-cell clones specific for the conserved epitope from the
matrix protein (M158–66, restricted by HLA-A
*0201) and the
HLA-B*2705-restricted NP383–391 epitope. As expected, the CTL
clone specific for the original NP383–391 epitope recognized target
cells infected with influenza virus A/NL/94-384R and failed to
recognize those infected with influenza virus A/NL/94-384G (Fig.
1B). In contrast, the CTL clone specific for M158–66 recognized
A/NL/94-384G- and A/NL/94-384R-infected target cells equally
well, indicating that the infection of cells and the processing and
presentation of immunogenic peptides were comparable for both
viruses (Fig. 1A).
In vitro stimulation of PBMC with recombinant influenza
viruses. Viruses A/NL/94-384G and A/NL/94-384R were used
for the stimulation of PBMC obtained from an HLA-A*0201-
and HLA-B*2705-positive blood donor to demonstrate that
the R384G mutation resulted in the depletion of a CTL re-
sponse against the NP383–391 epitope. As shown in Fig.2A to H,
stimulation with A/NL/94-384G or A/NL/94-384R resulted in
similar numbers of IFN- CD8 T cells specific for the
conserved HLA-A*0201-restricted M158–66 epitope and the
HLA-B*2705-restricted NP174–184 epitope, as measured after
restimulation with peptide-pulsed BLCL. In contrast, the re-
sponse to NP383–391 was virtually absent in PBMC cultures
stimulated with influenza virus A/NL/94-384G but not in those
stimulated with influenza virus A/NL/94-384R. In the PBMC
of donor 2, 10.6% of the CD8 T cells were specific for the
NP383–391 epitope (Fig. 2H). Similar results were observed for
the other donors. The absence of CD8 T cells specific for the
NP383–391 epitope, as measured by intracellular IFN- staining,
coincided with the lack of capacity of the PBMC culture to lyse
target cells pulsed with the NP383–391 peptide but not those
pulsed with the M158–66 peptide or the NP174–184 peptide (Fig.
2, bottom panels).
Magnitude of the influenza virus-specific CTL response in
vitro. The contribution of the NP383–391 epitope to the influ-
enza A virus-specific CTL response was determined by mea-
suring the proportions of CD3 CD8 IFN- cells in PBMC
cultures stimulated with influenza virus A/NL/94-384G or
A/NL/94-384R. IFN- expression was induced by restimulation
with autologous BLCL or C1R-B27 cells infected with the
respective influenza viruses or incubated with rNP or peptides.
Figure 3 shows such an analysis for donor 2 after restimulation
with autologous BLCL. A response was observed after re-
stimulation with BLCL incubated with the NP383–391 peptide
or rNP-HK in PBMC cultures expanded after stimulation
with influenza virus A/NL/94-384R. Such a response was not
observed after restimulation with rNP-NL, which lacks the
NP383–391 epitope (Fig. 3, right). After primary stimulation
with influenza virus A/NL/94-384G, no response was observed
after restimulation with the NP383–391 peptide or rNP (Fig. 3,
left). In addition, no differences were observed for the influ-
enza virus A/NL/94-384G-stimulated culture in the in vitro
recall response induced by influenza viruses A/NL/94-384G
and A/NL/94-384R. However, the CTL response against influ-
enza virus A/NL/94-384G was significantly lower than the re-
sponse to influenza virus A/NL/94-384R in PBMC cultures that
were stimulated with influenza virus A/NL/94-384R.
These differences are depicted for all donors tested as the
percentage of virus-specific IFN- CD8 T cells in PBMC cul-
tures (Fig. 4A) and as the percentage of virus-specific IFN-
cells in the CD8-T-cell fraction (Fig. 4B), ranging from 1 to 9%
and 1 to 20%, respectively. Since no differences were observed
after primary stimulation with a virus lacking the NP383–391 epi-
tope, these results show that depletion of this epitope resulted in
a substantial decrease in the influenza A virus-specific CTL re-
sponse in vitro. The relative reduction in the CTL response in-
FIG. 1. Recognition of BLCL infected with recombinant influenza
viruses by CTL clones. HLA-A*0201- and HLA-B*2705-positive BLCL
were infected with influenza virus A/NL/94-384G (E) or A/NL/94-
384R (F), pulsed with M158–66 (‚) or NP383–391 (Œ) peptide or left
untreated (), and used as target cells for CD8-T-cell clones
specific for the HLA-A*0201-restricted M158–66 epitope (A) and the
HLA-B*2705-restricted NP383–391 epitope (B) in a
51Cr release assay.
CTL clones were added at different E/T ratios as indicated, and spe-
cific lysis was calculated.
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duced by the virus without the NP383–391 epitope compared to the
response against the virus with the NP383–391 epitope ranged from
2 to 46%, with a median of 30% (Fig. 4).
When C1R-B27 cells were used for the restimulation of
PBMC cultures stimulated with influenza virus A/NL/94-384G
or A/NL/94-384R, comparable results were obtained (data not
shown). As expected, the percentage of virus-specific CTL
restricted by a single HLA allele was lower than the percentage
measured after restimulation with autologous BLCL. On av-
erage, the HLA-B*2705-restricted response constituted 65% of
the response measured over all HLA alleles when autologous
BLCL were used.
PBMC cultures stimulated with influenza viruses A/NL/94-
384G and A/NL/94-384R were also tested in parallel in 51Cr
release assays. In contrast to the results obtained with intracellu-
lar IFN- staining, no clear differences were observed for the lysis
of target cells infected with influenza virus A/NL/94-384G or
A/NL/94-384R by PBMC expanded after stimulation with influ-
enza virus A/NL/94-384R (Fig. 5A and B). However, when pro-
tein-labeled BLCL or C1R-B27 cells were used as target cells,
PBMC cultures stimulated with influenza virus A/NL/94-384R
recognized target cells labeled with rNP-HK but failed to recog-
nize target cells labeled with rNP-NL, containing the R384G
mutation (Fig. 5D). PBMC cultures stimulated with influenza
virus A/NL/94-384G failed to recognize protein-labeled target
cells at all (Fig. 5C). These findings indicate that the NP383–391
epitope constitutes an important CTL epitope recognized in the
NP-specific CTL response of these donors.
FIG. 2. IFN- expression and lysis by CD3 CD8 cells after stim-
ulation of PBMC with influenza virus A/NL/94-384G or A/NL/94-
384R. (A to H) PBMC from an HLA-A*0201- and HLA-B*2705-
positive donor, expanded after stimulation with influenza virus A/NL/
94-384G (A, C, E, and G) or A/NL/94-384R (B, D, F, and H), were
restimulated with BLCL pulsed with the M158–66 epitope (C and D),
the NP174–184 epitope (E and F), or the NP383–391 epitope (G and H).
Restimulation with untreated cells was used as a negative control (A
and B). Virus-specific CTL were visualized after staining with MAbs
specific for CD3, CD8, and IFN-. The data represent the percentages
of IFN- cells (IFN--PE) within the CD8-T-cell population. FITC,
fluorescein isothiocyanate. (Bottom panels) CTL specific for the
M158–66 epitope (Œ), the NP174–184 epitope (E), and the NP383–391
epitope (F) were also detected by a 51Cr release assay with peptide-
pulsed BLCL as target cells and PBMC cultures stimulated with A/NL/
FIG. 3. Percentages of virus-specific CD8 T cells in PBMC cul-
tures stimulated in vitro. The percentages of IFN- CD8 T cells in
PBMC from donor 2 were determined after stimulation in vitro with
influenza virus A/NL/94-384G (left) or A/NL/94-384R (right), without
or with the HLA-B*2705-restricted NP383–391 epitope, respectively.
Expanded cells were restimulated with autologous BLCL that were
infected with influenza virus A/NL/94-384G or A/NL/94-384R or that
were incubated with peptide NP383–391 (SRYWAIRTR), rNP-HK, or
rNP-NL. Virus-specific CTL were visualized after staining with MAbs
specific for CD3, CD8, and IFN-. The data represent the proportions
of CD3 CD8 IFN- cells in total PBMC cultures. These values
were calculated as the product of the percentage of IFN- cells in the
CD3 CD8 fraction multiplied by the percentage of CD8 T cells in
the PBMC culture. Error bars indicate standard deviations.
94-384G (left) or A/NL/94-384R (right). Untreated cells were included
as negative controls (). Effector cells were added at different E/T
ratios as indicated, and specific lysis was calculated.
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DISCUSSION
In the present study, the effect of a single amino acid sub-
stitution in epitope NP383–391 on the in vitro human CTL re-
sponse specific for influenza A virus was investigated by using
recombinant influenza viruses differing only at position 384 of
the NP. When these influenza viruses were used for the stim-
ulation of PBMC obtained from HLA-B*2705-positive individ-
uals, it was found that the mutation reduced the magnitude of
the virus-specific CTL response in vitro.
Before influenza viruses A/NL/94-384G and A/NL/94-384R
were compared for their capacities to induce CTL responses in
vitro, it was confirmed that BLCL and C1R cells were equally
susceptible to infection with these two viruses and that the
antigen processing and presentation of MHC class I peptide
complexes on the surface of these cells were on the same order
of magnitude when a CTL clone specific for the M158–66 epi-
tope was used. Furthermore, the presence and absence of
the NP383–391 epitope in influenza viruses A/NL/94-384R
and A/NL/94-384G, respectively, were confirmed by using
an NP383–391-specific CTL clone and PBMC that were ob-
tained from HLA-B*2705-positive individuals and that were
stimulated in vitro with these viruses.
Stimulation of HLA-B*2705-positive PBMC with influenza vi-
rus A/NL/94-384G did not result in stronger responses against
FIG. 4. Reduction of the in vitro CTL response through loss of the
NP383–391 epitope. (A) Reduction () in the percentages of virus-
specific IFN- CD8 T cells in PBMC cultures stimulated with in-
fluenza virus A/NL/94-384G or A/NL/94-384R for all five donors. Re-
duction was calculated by subtracting the percentage of IFN- CD8
T cells after restimulation with influenza virus A/NL/94-384G from the
percentage of IFN- CD8 T cells after restimulation with influenza
virus A/NL/94-384R. The percentage of IFN- CD8 T cells in
PBMC cultures was determined as indicated in the legend to Fig. 3.
(B) Reduction expressed as the difference in the percentages of virus-
specific IFN- T cells within the CD3 CD8 fraction of PBMC cul-
tures, as measured by flow cytometry. (C) Reduction in the percent-
ages of virus-specific IFN- CD8 T cells in PBMC cultures calculated
as relative reduction as follows: 100  [(percentage of IFN- CD8
T cells after restimulation with influenza virus A/NL/94-384G  100)/
percentage of IFN- CD8 T cells after restimulation with influenza
virus A/NL/94-384R]. In all three panels, the average is shown as a
horizontal bar. Numbers refer to the donors listed in Table 2.
FIG. 5. Recognition of BLCL infected with influenza viruses (A
and B) or incubated with rNP (C and D) by in vitro-stimulated PBMC
obtained from donor 2. PBMC expanded after stimulation with influ-
enza virus A/NL/94-384G (A and C) or A/NL/94-384R (B and D) were
used as effector cells in 51Cr release assays. Autologous BLCL infected
with influenza virus A/NL/94-384G (E) or A/NL/94-384R (F) or BLCL
incubated with rNP derived from influenza virus A/NL/18/94 (‚) or
A/HK/2/68 (Œ) were used as target cells. Untreated cells were included
as negative controls (). The data represent the percentages of specific
lysis at the indicated E/T ratios.
TABLE 1. Known influenza A virus CTL epitopes likely recognized
by the five individuals included in this studya
HLA restriction Protein (amino acids) Amino acid sequence
A*01 PB1 (591–599) VSDGGPNLY
NP (44–52) CTELKLSDY
A*0201 M1 (58–66) GILGFVFTL
NS1 (122–130) AIMDKNIIL
NA (213–221) CVNGSCFTV
PA (46–54) FMYSDFHFI
PA (225–233) SLENFRAYV
PB1 (413–421) NMLSTVLGV
NA (75–84) SLCPIRGWAI
A*03 NP (265–273) ILRGSVAHK
M1 (27–35) RLEDVFAGK
A*1101 HA (63–70) GIAPLQLGK
HA (149–158) VTAACSHAGK
HA (450–460) RTLDFHDSNVK
M1 (13–21) SIIPSGPLK
NP (188–198) TMVMELVRMIK
B*08 NP (380–388) ELRSRYWAI
B*2705 NP (383–391) SRYWAIRTR
NP (174–184) RRSGAAGAAVK
a Data are from the Influenza Sequence Database (http://www.flu.lanl.gov) (26).
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conserved epitopes NP174–184 and M158–66 than did stimulation
with influenza virus A/NL/94-384R, indicating that the loss of one
HLA-B*2705-restricted epitope was not compensated for by the
response to another in this in vitro system. In PBMC cultures of
five HLA-B*2705-positive individuals, expanded after stimulation
with influenza virus A/NL/94-384R, CD8 T cells specific for the
NP383–391 peptide and rNP-HK but not rNP-NL were demon-
strated. The results obtained with rNP-HK or rNP-NL in intra-
cellular IFN- staining and 51Cr release assays indicated that the
NP383–391 epitope is the most immunodominant epitope in the
NP restricted by HLA-B*2705 and other alleles expressed in the
individuals tested (HLA-A*0101, HLA-A*0201, HLA-A*0301,
HLA-A*1101, HLA-A*2301, HLA-A*3101, HLA-B*0801, and
HLA-B*4101) (Tables 1 and 2). The responses to influenza virus
A/NL/94-384G were similar in PBMC stimulated with influenza
viruses A/NL/94-384G and A/NL/94-384R. However, in PBMC
stimulated with influenza virus A/NL/94-384R, a lower frequency
of influenza virus A/NL/94-384G-specific cells than of influenza
virus A/NL/94-384R-specific cells was observed. This difference
was used as a measure of the reduction in the virus-specific CTL
response by the loss of the NP383–391 epitope. In four out of five
donors tested, a significant reduction in the number of influenza
A virus-specific CD8 CTL was measured. Thus, the loss of a
single epitope can have a major impact on the CTL response in
vitro. The absence of a reduction in donor 1 correlated with the
subdominant nature of the NP383–391 epitope in this donor (Table
2). Overall, there was a correlation between the frequency of
NP383–391-specific CTL in PBMC cultures stimulated with A/NL/
94-384R and the reduction in the CTL response after stimulation
with an influenza virus lacking the NP383–391 epitope.
Since three of the five donors tested were also HLA-B*0801
positive, it is possible that the loss of the HLA-B*0801-re-
stricted NP380–388 epitope also contributed to the reduction in
the CTL response in these donors. It should be noted, how-
ever, that the NP380–388 epitope is a minor epitope, especially
in the presence of an HLA-B*2705-restricted response (4);
therefore, its loss could be only marginally responsible for the
observed reduction in the CTL response.
The differences in CTL responses measured by intracellular
IFN- staining were not detected in 51Cr release assays when
virus-infected BLCL were used as target cells. The resolution
of the 51Cr release assays may not be sufficient to detect such
differences, considering the reduction in frequency (1 to 9%)
of virus-specific cells in the in vitro-expanded PBMC (which
were used as effector cells in these assays) caused by the de-
letion of the NP383–391 epitope.
Based on these data, we conclude that the mutation in the
NP383–391 epitope impaired the overall in vitro CTL response
directed against influenza virus significantly. However, it is not
clear from these studies what the impact of the R384G muta-
tion on the in vivo CTL response in humans is. Of interest, it
was recently demonstrated with a mouse model for influenza
virus that deletion of a dominant H-2Db-restricted epitope
from the NP (NP366–374) of influenza A viruses by site-directed
mutagenesis resulted in the loss of a CTL response specific for
this epitope in vivo. This finding correlated with a prolonged
duration of viral shedding in infected mice and increased mor-
tality rates (43). Furthermore, the loss of an immunodominant
epitope was responsible for prolonged viral shedding (up to 2
months) in RAG-1-deficient mice transgenic for the T-cell
receptor specific for that epitope (35). If infection of humans
also results in reduced control of an infection with CTL epi-
tope mutant influenza viruses, it might be expected that HLA-
B*2705-positive individuals would be more susceptible to in-
fection with a mutant virus (lacking the NP383–391 epitope)
than with a wild-type virus. Of interest, prolonged viral shed-
ding in a small proportion of individuals in the human popu-
lation (e.g., 8% HLA-B*2705 positive) was sufficient to ex-
plain the rapid fixation of the R384G substitution in the CTL
NP383–391 epitope at the population level with a recently de-
veloped theoretical model (16, 41).
Collectively, the data obtained in the present study showed
that the loss of an immunodominant epitope through a muta-
tion at an anchor residue affects the CTL response in vitro
significantly. It could be speculated that the emergence of
influenza A viruses with mutations in CTL epitopes have a
profound advantage in individuals expressing the correspond-
ing HLA molecules, eventually leading to the rapid fixation of
these mutants (16).
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